Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
The Second Hospital of Anhui Medical University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01661322CT.gov Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke | — | Terminated | — | — | — |
NCT00562588CT.gov EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA | — | Completed | — | — | — |
NCT00311402CT.gov JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme | — | Completed | — | — | — |
NCT00238667CT.gov To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection | — | Completed | — | — | — |
NCT00153062CT.gov PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dipyridamole (this asset) | The Second Hospital of Anhui Medical University | Approved | BB · 66 |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Aspirin | China National Center for Cardiovascular Diseases | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Dipyridamole
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P4 | BB · 71 |
| Brain Ischemia | — | P4 | BB · 68 |
| Portal Hypertension | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dipyridamole in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dipyridamole-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →